Isis gains on more data for ISIS-APOCIIIRx

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) gained $3.51 to $43.21 on Monday after the company presented more data from a Phase II trial of once-weekly subcutaneous ISIS-APOCIIIRx for 13 weeks to treat hypertriglyceridemia. The company said ISIS-APOCIIIRx led to significant mean percent reductions in apolipoprotein C-III ( APOCIII; APOC3) and triglyceride levels from baseline to at least six weeks after the end of treatment vs. placebo in a cohort of 26 patients with high to severely high triglyceride levels (225-2,000 mg/dL) on stable doses of fibrates. The updated data were presented at the American College of Cardiology meeting.

Last year, Isis reported data from the cohort showing that both doses of ISIS-APOCIIIRx met the co-primary endpoints of reducing APOCIII and triglyceride levels from baseline to week 13 vs. placebo (see BioCentury Extra, July 22, 2013). ...